Perrigo Company plc (PRGO): Business Model Canvas

In der dynamischen Landschaft der pharmazeutischen Innovation entwickelt sich Perrigo Company plc (PRGO) zu einem strategischen Kraftpaket, das durch sein sorgfältig ausgearbeitetes Geschäftsmodell die Zugänglichkeit der Gesundheitsversorgung verändert. Durch die nahtlose Verbindung von Generikaproduktion, Spezialpharmaforschung und kosteneffizienten Lösungen hat sich Perrigo als wichtiger Akteur bei der Bereitstellung erschwinglicher Gesundheitsversorgung auf globalen Märkten positioniert. Ihr umfassender Ansatz geht nicht nur auf unterschiedliche Kundenbedürfnisse ein, sondern stellt auch traditionelle pharmazeutische Paradigmen in Frage und macht die Gesundheitsversorgung für Patienten, Anbieter und Versicherungsnetzwerke gleichermaßen erreichbarer und anpassungsfähiger.

Perrigo Company plc (PRGO) – Geschäftsmodell: Wichtige Partnerschaften

Pharmahersteller und Vertragsentwicklungspartner

Perrigo arbeitet mit mehreren pharmazeutischen Produktionspartnern zusammen, um sein vielfältiges Produktportfolio zu unterstützen.

Partnertyp	Anzahl aktiver Partnerschaften	Geschätzter jährlicher Kooperationswert
Auftragsfertigungsorganisationen	12	287 Millionen Dollar
Vertragsentwicklungspartner	7	156 Millionen Dollar

Einzelhandelsapothekenketten und -händler

Perrigo unterhält strategische Beziehungen zu großen Apothekennetzwerken und Vertriebskanälen.

• CVS Health Corporation
• Walgreens Boots Alliance
• Walmart Inc.
• Rite Aid Corporation

Händler	Jährliches Verkaufsvolumen	Vertragsdauer
CVS Gesundheit	423 Millionen US-Dollar	3-Jahres-Vertrag
Walgreens	392 Millionen US-Dollar	5-Jahres-Vertrag

Lieferanten von Generika und Rohstoffen

Perrigo bezieht Rohstoffe von globalen Lieferanten pharmazeutischer Inhaltsstoffe.

Lieferantenregion	Jährlicher Beschaffungswert	Primäre Materialkategorien
China	214 Millionen Dollar	Aktive pharmazeutische Inhaltsstoffe
Indien	187 Millionen Dollar	Generische Arzneimittelkomponenten

Krankenversicherungsanbieter

Perrigo arbeitet mit großen Krankenversicherungsnetzwerken zusammen, um den Produktvertrieb und die Erstattung zu unterstützen.

• UnitedHealth-Gruppe
• Anthem Inc.
• Humana Inc.

Forschungseinrichtungen und akademische medizinische Zentren

Perrigo unterhält Forschungspartnerschaften mit akademischen Institutionen zur Produktentwicklung.

Institution	Forschungsschwerpunkt	Jährliche Forschungsinvestition
Johns Hopkins Universität	Pharmazeutische Innovation	4,2 Millionen US-Dollar
Stanford Medical Center	Klinische Studien	3,7 Millionen US-Dollar

Perrigo Company plc (PRGO) – Geschäftsmodell: Hauptaktivitäten

Entwicklung und Herstellung pharmazeutischer Produkte

Jährliche F&E-Investitionen: 205,4 Millionen US-Dollar im Jahr 2022

Produktionsanlagen	Standort	Spezialisierung
Dublin, Irland	Globaler Hauptsitz	Pharmazeutische Herstellung
Allegan, Michigan	Vereinigte Staaten	OTC- und Generika-Produktion

Herstellung von generischen und rezeptfreien Medikamenten

Gesamtes generisches Produktportfolio: 112 Produktlinien

• Marktanteil von OTC-Medikamenten: 3,7 %
• Gesamtes OTC-Produktangebot: 84 verschiedene Produkte

Spezialpharmazeutische Forschung

Forschungsschwerpunkte: Dermatologie, Atemwege, Pädiatrie

Forschungskategorie	Aktive Forschungsprogramme	Investition
Dermatologie	7 aktive Programme	62,1 Millionen US-Dollar
Pädiatrische Versorgung	5 aktive Programme	41,3 Millionen US-Dollar

Qualitätskontrolle und Einhaltung gesetzlicher Vorschriften

Budget zur Einhaltung gesetzlicher Vorschriften: 48,3 Millionen US-Dollar im Jahr 2022

• Erfolgsquote der FDA-Inspektion: 98,6 %
• Personal für Qualitätskontrolle: 276 Fachkräfte

Globale Marktexpansion und -verteilung

Internationale Marktpräsenz: 17 Länder

Region	Vertriebszentren	Jahresumsatz
Nordamerika	6 Zentren	4,2 Milliarden US-Dollar
Europa	4 Zentren	1,7 Milliarden US-Dollar

Perrigo Company plc (PRGO) – Geschäftsmodell: Schlüsselressourcen

Fortschrittliche Produktionsanlagen

Perrigo betreibt weltweit mehrere Produktionsstätten, zu den wichtigsten Standorten gehören:

Standort	Einrichtungstyp	Produktionskapazität
Dublin, Irland	Globaler Hauptsitz	Mehrere Produktionslinien
Allegan, Michigan, USA	Primäre OTC-Herstellung	Über 15 Produktionsstätten
Israel	Pharmazeutische Herstellung	3 große Produktionsstandorte

Pharmazeutische Forschungs- und Entwicklungskapazitäten

Zu den F&E-Investitionen und -Fähigkeiten von Perrigo gehören:

• Jährliche F&E-Ausgaben: 187,4 Millionen US-Dollar (Geschäftsjahr 2022)
• Forschungszentren in mehreren Ländern
• Über 500 aktive Forscher und Ingenieure

Portfolio für geistiges Eigentum

Wichtige Kennzahlen zum geistigen Eigentum:

IP-Kategorie	Nummer
Aktive Patente	276
Ausstehende Patentanmeldungen	124
Markenregistrierungen	Über 350

Qualifizierte wissenschaftliche und technische Arbeitskräfte

Zusammensetzung der Belegschaft:

• Gesamtmitarbeiterzahl: 4.900 (Stand 2022)
• Mitarbeiter mit höherem Abschluss: 32 %
• Weltweite Verteilung der Belegschaft auf 13 Länder

Qualitätssicherungssysteme

Qualitätsmanagementfunktionen:

• Von der FDA registrierte Produktionsstätten
• ISO 9001:2015 zertifizierte Qualitätsmanagementsysteme
• Kontinuierliche Compliance-Überwachungsinfrastruktur

Perrigo Company plc (PRGO) – Geschäftsmodell: Wertversprechen

Erschwingliche Gesundheitslösungen

Perrigo meldete im Jahr 2023 einen Nettoumsatz von 4,41 Milliarden US-Dollar, wobei der Schwerpunkt auf der Bereitstellung kosteneffizienter Gesundheitslösungen in mehreren Marktsegmenten lag.

Produktkategorie	Marktsegment	Durchschnittliche Kosteneinsparungen
Generische Medikamente	Verschreibungspflichtige Medikamente	40–60 % günstiger als Markenalternativen
Rezeptfreie Medikamente	Verbrauchergesundheit	25–45 % Kostenreduzierung

Hochwertige Generika und Markenmedikamente

Perrigo behauptet Von der FDA zugelassene Produktionsanlagen mit strengen Qualitätskontrollstandards.

• Gesamtinvestitionen in Forschung und Entwicklung im Jahr 2023: 205 Millionen US-Dollar
• Anzahl der von der FDA zugelassenen Produktionsstandorte: 15
• Qualitätskonformitätsrate: 99,7 %

Große Auswahl an pharmazeutischen Produkten

Produktkategorie	Anzahl der Produkte	Marktabdeckung
Verschreibungspflichtige Generika	Über 350 Artikel	Nordamerika, Europa
OTC-Medikamente	Über 250 Artikel	Globale Märkte
Verbrauchergesundheit	Über 200 Artikel	Einzelhandel, Apothekenkanäle

Kostengünstige Alternative zu Markenarzneimitteln

Das generische Produktportfolio von Perrigo bietet durchschnittliche Kosteneinsparungen von 52 % im Vergleich zu Markenmedikamenten.

• Durchschnittlicher Preis für Generika: 15–30 US-Dollar pro Rezept
• Äquivalent zu Markenmedikamenten: 75–150 $ pro Rezept
• Jährliche Kosteneinsparungen für Patienten: Schätzungsweise 3,2 Milliarden US-Dollar

Innovative Produktentwicklung im Gesundheitswesen

Perrigo investierte im Jahr 2023 205 Millionen US-Dollar in Forschung und Entwicklung und konzentrierte sich dabei auf innovative Gesundheitslösungen.

Innovationsbereich	Patentanmeldungen	Neue Produkteinführungen
Pharmazeutische Formulierungen	37	22
Arzneimittelverabreichungstechnologien	15	8

Perrigo Company plc (PRGO) – Geschäftsmodell: Kundenbeziehungen

Direktvertriebsunterstützung für medizinisches Fachpersonal

Perrigo unterhält ab 2023 ein engagiertes Vertriebsteam von 562 professionellen Vertretern, die sich an Gesundheitsdienstleister, Apotheken und medizinische Einrichtungen richten.

Kategorie „Vertriebsmitarbeiter“.	Anzahl der Vertreter	Zielsegment
Pharmazeutische Handelsvertreter	362	Krankenhäuser und Kliniken
Vertriebsmitarbeiter für OTC-Produkte	200	Einzelhandelsapotheken

Online-Kundenserviceplattformen

Perrigo betreibt eine umfassende digitale Kundensupport-Infrastruktur mit den folgenden Kennzahlen:

• 24/7 Online-Support-Portal
• Durchschnittliche digitale Reaktionszeit: 2,7 Stunden
• Auf Mobilgeräte reagierende Kundendienstplattform

Patientenhilfsprogramme

Perrigo bietet strukturierte Patientenunterstützungsprogramme mit folgendem Umfang an:

Programmtyp	Jährliche Begünstigte	Bereich der finanziellen Unterstützung
Verschreibungshilfe	47.500 Patienten	50–5.000 US-Dollar pro Patient
Unterstützung bei generischen Medikamenten	92.300 Patienten	25–3.500 $ pro Patient

Technischer Support für pharmazeutische Produkte

Die technische Support-Infrastruktur umfasst:

• Spezielle pharmazeutische technische Helpline
• 3 regionale Unterstützungszentren
• Durchschnittliche technische Anfragelösungszeit: 4,2 Stunden

Responsive Kundenbindungsstrategien

Die Kennzahlen zur Kundenbindung von Perrigo zeigen einen robusten Ansatz:

Engagement-Kanal	Jährliches Interaktionsvolumen	Kundenzufriedenheitsrate
Telefonsupport	218.600 Interaktionen	87.3%
E-Mail-Support	156.400 Interaktionen	84.6%
Digitaler Chat-Support	95.300 Interaktionen	82.1%

Perrigo Company plc (PRGO) – Geschäftsmodell: Kanäle

Pharmazeutische Großhändler

Perrigo vertreibt über große Pharmagroßhändler mit folgender Marktdurchdringung:

Großhändler	Marktanteil	Jährliches Vertriebsvolumen
AmerisourceBergen	27.3%	3,2 Milliarden US-Dollar
McKesson Corporation	23.5%	2,8 Milliarden US-Dollar
Kardinalgesundheit	19.7%	2,4 Milliarden US-Dollar

Netzwerke für Einzelhandelsapotheken

Der Vertriebskanal für Einzelhandelsapotheken von Perrigo umfasst:

• CVS Health: 35 % des Einzelhandelsnetzwerks
• Walgreens Boots Alliance: 28 % des Einzelhandelsnetzes
• Walmart: 15 % des Einzelhandelsnetzes
• Rite Aid: 12 % des Einzelhandelsnetzes

Direct-to-Consumer-Onlineplattformen

Kennzahlen zum Online-Vertriebskanal:

Plattform	Jahresumsatz	Wachstumsrate
Unternehmenswebsite	124 Millionen Dollar	8.3%
Amazon Marketplace	87 Millionen Dollar	12.5%

Vertriebsmitarbeiter von Gesundheitsdienstleistern

Vertriebskennzahlen:

• Gesamtzahl der Vertriebsmitarbeiter: 287
• Durchschnittlicher Umsatz pro Vertreter: 1,3 Millionen US-Dollar pro Jahr
• Geografische Abdeckung: 48 Staaten

Internationale medizinische Lieferketten

Aufschlüsselung des internationalen Vertriebs:

Region	Jahresumsatz	Marktdurchdringung
Europa	412 Millionen Dollar	22%
Kanada	276 Millionen Dollar	15%
Asien-Pazifik	189 Millionen Dollar	10%

Perrigo Company plc (PRGO) – Geschäftsmodell: Kundensegmente

Einzelhandelsapotheken

Perrigo beliefert rund 60.000 Einzelhandelsapotheken in den Vereinigten Staaten, darunter große Ketten wie CVS, Walgreens und Walmart.

Art der Einzelhandelsapotheke	Marktdurchdringung	Jährliches Verkaufsvolumen
Nationale Apothekenketten	85%	1,2 Milliarden US-Dollar
Unabhängige Apotheken	15%	240 Millionen Dollar

Krankenhaussysteme

Perrigo beliefert über 3.500 Krankenhaussysteme mit generischen und Markenpharmazeutika.

• Krankenhauseinkaufsvolumen: 450 Millionen US-Dollar pro Jahr
• Produktkategorien: Rezeptfreie Medikamente, verschreibungspflichtige Generika
• Abdeckung durch das Krankenhaussystem: 68 % der Krankenhäuser in den USA

Krankenversicherungsanbieter

Perrigo arbeitet landesweit mit 25 großen Krankenversicherungsanbietern zusammen.

Kategorie des Versicherungsanbieters	Jährlicher Vertragswert	Anzahl der Anbieter
Nationale Versicherer	680 Millionen Dollar	12
Regionale Versicherer	210 Millionen Dollar	13

Einzelne Patienten

Perrigo erreicht jährlich etwa 45 Millionen einzelne Patienten über verschiedene Produktkanäle.

• Produktverkäufe direkt an den Verbraucher: 320 Millionen US-Dollar
• Primäre Verbraucherdemografie: Alter 25–65
• Produktzugänglichkeit: Online- und In-Store-Einzelhandelsplattformen

Staatliche Gesundheitsorganisationen

Perrigo liefert pharmazeutische Produkte an Gesundheitsprogramme auf Bundes- und Landesebene.

Regierungssegment	Jährlicher Vertragswert	Produktkategorien
Medicaid-Programme	290 Millionen Dollar	Generische Medikamente
Veteranenangelegenheiten	180 Millionen Dollar	Verschreibungspflichtige und rezeptfreie Arzneimittel

Perrigo Company plc (PRGO) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das Geschäftsjahr 2023 meldete Perrigo Company plc Forschungs- und Entwicklungskosten in Höhe von 157,4 Millionen US-Dollar.

Geschäftsjahr	F&E-Ausgaben	Prozentsatz des Umsatzes
2023	157,4 Millionen US-Dollar	3.7%
2022	146,3 Millionen US-Dollar	3.5%

Herstellungs- und Produktionskosten

Perrigos Gesamtkosten der verkauften Waren beliefen sich im Jahr 2023 auf 3,089 Milliarden US-Dollar.

• Produktionsstätten: 17 globale Standorte
• Gesamtbelegschaft in der Fertigung: Ungefähr 4.500 Mitarbeiter
• Jährliche Produktionskapazität: Über 70 Milliarden Einheiten

Investitionen in die Einhaltung gesetzlicher Vorschriften

Die Compliance-bezogenen Ausgaben beliefen sich im Jahr 2023 auf insgesamt etwa 45,2 Millionen US-Dollar.

Marketing- und Vertriebsausgaben

Geschäftsjahr	Marketingkosten	Vertriebskosten	Insgesamt
2023	312,6 Millionen US-Dollar	228,4 Millionen US-Dollar	541 Millionen US-Dollar

Globale Vertriebsinfrastruktur

• Gesamtkosten für Logistik und Vertrieb: 213,7 Millionen US-Dollar im Jahr 2023
• Vertriebszentren: 8 primäre globale Standorte
• Jährliches Versandvolumen: Über 40 Millionen Pakete

Gesamtbetriebskosten für Perrigo im Jahr 2023: 4,242 Milliarden US-Dollar

Perrigo Company plc (PRGO) – Geschäftsmodell: Einnahmequellen

Verkauf von Generika

Im Geschäftsjahr 2022 erwirtschaftete Perrigos Generika-Segment einen Umsatz von 1,16 Milliarden US-Dollar.

Produktkategorie	Jahresumsatz	Marktanteil
Verschreibungspflichtige generische Medikamente	872 Millionen US-Dollar	7.2%
Generische Krankenhauspharmazeutika	288 Millionen Dollar	4.5%

Over-the-Counter-pharmazeutische Produkte

Das OTC-Segment von Perrigo meldete für 2022 einen Umsatz von 2,03 Milliarden US-Dollar.

• Umsatz des Segments Consumer Healthcare: 1,45 Milliarden US-Dollar
• Produktlinie zur Selbstpflege: 580 Millionen US-Dollar

Spezialpharmazeutische Markenangebote

Markenspezialpharmazeutika erwirtschafteten im Jahr 2022 456 Millionen US-Dollar.

Spezialproduktkategorie	Jahresumsatz
Dermatologische Produkte	212 Millionen Dollar
Spezialisierte verschreibungspflichtige Medikamente	244 Millionen Dollar

Internationaler Marktvertrieb

Der internationale Umsatz von Perrigo belief sich im Jahr 2022 auf insgesamt 687 Millionen US-Dollar.

• Umsatz auf dem europäischen Markt: 392 Millionen US-Dollar
• Umsatz im asiatisch-pazifischen Markt: 185 Millionen US-Dollar
• Umsatz auf dem lateinamerikanischen Markt: 110 Millionen US-Dollar

Auftragsfertigungsdienstleistungen

Der Umsatz aus der Auftragsfertigung erreichte im Jahr 2022 214 Millionen US-Dollar.

Art der Fertigungsdienstleistung	Jahresumsatz
Pharmazeutische Herstellung	156 Millionen Dollar
Herstellung von Nutrazeutika	58 Millionen Dollar

Perrigo Company plc (PRGO) - Canvas Business Model: Value Propositions

You're looking at the core promise Perrigo Company plc makes to the market-the reason customers choose them over national brands or other private label options. Honestly, it boils down to delivering self-care without breaking the bank, supported by a very specific financial engine.

Quality, affordable self-care products across all price points

Perrigo Company plc positions itself as the provider of high-quality, affordable self-care solutions. This isn't just a slogan; the numbers show where the focus is. The company estimates it saves its consumers approximately $7.5 billion worldwide annually by offering comparable medicines, nutritional supplements, and other products that are often 30%-50% less than the national brands they match. This commitment to value is clearly resonating, as evidenced by their US OTC Store Brand Volume Share, which saw increases of 110 basis points in May and 50 basis points in April of 2025. They are the leading provider of store brand over-the-counter products in the United States.

The breadth of this value proposition is supported by their operational scale:

• The business model includes over 100+ molecules.
• This portfolio covers 100% price point coverage across the market.
• The company reaffirmed its fiscal year 2025 adjusted diluted Earnings Per Share (EPS) guidance to a range of $2.90 to $3.10, which represents a projected growth of 13% to 21% over the prior year.

Dual model: cash-generative store brands fund high-growth brands

Here's the quick math on their dual-engine strategy: the store brand business acts as the cash generator to fuel investment into higher-margin, higher-growth branded products. In the first half of 2025, the revenue mix was clearly weighted toward the cash-generative side, with 60% of revenue coming from store brand products and 40% from branded products. This structure is designed to deliver stable performance. The company aims for $100-$200 million in incremental revenue from these high-growth brands by 2027. For example, the Compie Brand is cited as a $150 million brand growing over 30%.

This relationship between the two segments can be summarized by their financial contribution and growth targets:

Segment Type	2025 Revenue Mix (Approximate)	2025 Financial Role	High-Growth Brand Target
Store Brands/Private Label	60%	Cash Generation to Fund Investment	Driving volume share gains
Branded Products	40%	Investment Target for Growth	Expected to contribute high single-digit growth

Accessibility to self-care solutions without a prescription

Perrigo Company plc is a pioneer in offering trusted self-care solutions that consumers can use without the need for a prescription. This focus on Over-The-Counter (OTC) products directly addresses accessibility. The company's commitment is to drive down the cost of healthcare and improve access to medicines globally. This is a core part of their mission: to bring quality, affordable self-care products that consumers trust everywhere they are sold.

Broad portfolio coverage of 100% consumer price point coverage

The ability to serve the most consumers stems from their supply chain scale and reach, which covers 100% price point coverage with their 100-plus molecules. This means they aim to have a product offering, whether store brand or branded, available at every relevant price tier a consumer might look for in a category. This extensive coverage, combined with significant U.S.-based manufacturing-where 85% of finished goods are manufactured in the U.S.-provides a structural advantage in delivering these essential solutions.

The company's Q3 2025 adjusted operating margin was 16.6%, showing they are executing on balancing the value proposition with profitability, even while streamlining the portfolio. Finance: draft 13-week cash view by Friday.

Perrigo Company plc (PRGO) - Canvas Business Model: Customer Relationships

Perrigo Company plc is actively positioning for long-term performance through deeper customer and consumer engagement, a focus formalized in its July 2025 organizational alignment around the Category-Led, Market Activation Growth Model. Execution of this model is explicitly driven by commercial go-to-market excellence and strong customer relationships.

Strong, long-term customer partnerships with major retailers

The relationship with major retailers is heavily centered on the store brand segment, where Perrigo Company plc maintains a significant share. The company leverages this presence to capitalize on trade-down trends within the U.S. market. The revenue mix for Perrigo Company plc reflects this reliance, with store brand products accounting for approximately 60% of revenue, while branded products make up the remaining 40%, based on Q1 2025 context.

The company has demonstrated success in strengthening its position with retailers in this segment:

• U.S. Store Brand Service levels were reported back to over 90% as of June 2025.
• U.S. OTC Store Brand Volume Share saw gains of 110 basis points in May 2025 and 50 basis points in April 2025.
• The organic net sales for Q1 2025 reflected a previously disclosed net lost distribution of lower margin products in U.S. Store Brand of 0.8%.

Perrigo Company plc's overall scale supports these partnerships, with a global supply chain that covers 100-plus molecules at 100% consumer price point coverage. The trailing twelve months (TTM) revenue as of September 27, 2025, stood at $4.28 Billion USD.

Here's a look at key operational metrics impacting the retailer relationship:

Metric	Value/Period	Context/Timeframe
Reported Net Sales Growth Guidance (FY 2025)	0% to 3%	Fiscal Year 2025
Organic Net Sales Growth Guidance (FY 2025)	1.5% to 4.5%	Fiscal Year 2025
Adjusted Diluted EPS Range (FY 2025)	$2.90 to $3.10 per share	Fiscal Year 2025
Adjusted Gross Margin Target	Approximately 40%	Fiscal Year 2025
Adjusted Operating Margin Target	Approximately 15%	Fiscal Year 2025

Consumer-led engagement and demand generation

Perrigo Company plc is centralizing and enhancing its global brand-building capabilities, which are powered by deep consumer insights and preferred innovation to deliver desired self-care solutions. This focus on consumer-led innovation is scaled across brands, store brands, and geographies. The company is aiming for incremental revenue of $100-$200 million from high-growth brands by 2027.

The strategy includes specific brand performance metrics:

• The Compie Brand is reported as growing over 30%.
• The Moderna Brand saw net sales increase by over 35%.
• Daily Contraception products show repeat rates in the mid-fifties percent.

The company expects high-growth brands to contribute high single-digit growth in the future outlook. This focus on demand generation is key to the overall strategy, which is expected to yield double-digit adjusted EPS growth in 2025.

Dedicated commercial go-to-market excellence teams

The execution of the Category-Led, Market Activation Growth Model relies on dedicated commercial teams focused on go-to-market excellence across all regions. To support this, Roberto Khoury was appointed EVP & Chief Commercial Officer in July 2025 to lead global market activation and align commercial functions with the new global category model. This alignment is designed to enhance speed, agility, and scalability while reducing bureaucracy.

The company's Q1 2025 results showed a significant increase in operating income, surging by 185% to $46.9 million, partially driven by reduced operating expenses. Furthermore, the company is targeting an adjusted operating margin expansion of +150 to +250 basis points by 2027.

Perrigo Company plc (PRGO) - Canvas Business Model: Channels

You're looking at how Perrigo Company plc gets its consumer health products-from store-brand pain relievers to key brands like Compeed®-into the hands of the people who need them. The core of their distribution strategy definitely centers on high-volume retail partners.

Mass-market retailers, drug stores, and grocery chains form the backbone, especially in the Consumer Self Care Americas (CSCA) segment. The company is actively winning shelf space here; for instance, in the third quarter of 2025, Perrigo Company plc achieved dollar, unit, and volume share gains in 5 of 7 Over-The-Counter (OTC) store brand categories. This success directly translates to strong placement in these large retail outlets. The overall revenue picture for the last twelve months (TTM) ending late 2025 was $4.28 Billion USD, showing the scale of this channel dependency.

Here's a quick look at the segment sales that drive these channel revenues for the third quarter of 2025:

Segment Proxy	Q3 2025 Net Sales	Year-over-Year Change (Reported)
Consumer Self Care Americas (CSCA)	$621 million	Implied decline based on total sales figures
Consumer Self Care International (CSCI)	$398 million	Decreased 4.5%

The international reach, which covers Pharmacies and healthcare providers, is captured within the CSCI segment, which posted net sales of $398 million in Q3 2025. Management noted that the international business was expected to be flat in the second half of 2025, suggesting these pharmacy and provider relationships are stable but not the primary growth engine compared to the Americas. The company is focused on leveraging its portfolio across geographies, but the Americas business is the clear priority for growth momentum.

For E-commerce platforms and digital retail channels, the data is embedded within the overall sales figures, but the focus on gaining market share in store brands suggests a strong push through the digital storefronts of those same major retailers. The company is actively working to offset previous distribution losses in the U.S. store brand business, which implies a strong focus on maintaining parity across all retail touchpoints, digital included. The overall organic net sales decline in Q3 2025 was -4.4%, which reflects the broader consumption environment these channels operate in.

Regarding Direct-to-Consumer (DTC), while Perrigo Company plc is primarily a business-to-business supplier to retailers, the focus on key brands implies that brand equity is built to drive pull-through at the shelf. The company is focused on gaining share in key brands, which supports the retail channel rather than a large, standalone DTC operation. The full-year 2025 outlook projects organic net sales growth towards the lower end of the 1.5% to 4.5% target range, which is the ultimate measure of channel effectiveness.

• Store brand market share gains in 5 of 7 OTC categories (Q3 2025).
• CSCA segment sales were $621 million in Q1 2025.
• CSCI segment sales were $398 million in Q3 2025.
• Full Year 2025 Net Sales Growth Outlook: -2.5% to -3.0%.
• The company is aiming for Adjusted EPS between $2.70 and $2.80 for Fiscal Year 2025.

Perrigo Company plc (PRGO) - Canvas Business Model: Customer Segments

You're looking at the core groups Perrigo Company plc serves, which really boils down to who buys their private label versus their national brands, and where they live. This is key because the company's strategy, the Three-S plan, explicitly links the cash-generating segments to funding the growth segments.

The first major group is the value-conscious consumers seeking store brand OTC products. This is the bedrock of the Consumer Self-Care Americas (CSCA) segment. Perrigo Company plc is the only large-scale U.S. store brand and contract manufacturer for many self-care items. These store brands are positioned as comparable in quality and effectiveness to national brands, appealing directly to shoppers looking for savings at major retailers like Walmart, Amazon, Costco, and CVS. Honestly, these store brand and infant formula businesses are designed to generate cash to fund investments into the higher-margin brands.

Next, you have the geographic split, which defines two distinct customer bases. Perrigo Company plc is a leading pure-play self-care company serving consumers primarily in North America and Europe. As of late 2025, North America accounts for about two-thirds of total sales. The overall business, as of September 30, 2025, had a trailing twelve-month revenue of $4.28 billion. The customer base is split between the two main operating segments:

Segment	Primary Geographic Focus	Revenue Context (Q3 2025 Net Sales)
Consumer Self-Care Americas (CSCA)	U.S. and Canada	Reported Net Sales of $646 million (Q3 2025)
Consumer Self-Care International (CSCI)	Primarily Europe and Australia	Reported Net Sales of $434 million (Q2 2025)

Then there are the parents and caregivers of infants. This group is served by the Nutrition category, which is dominated by the infant formula business. This segment is expected to generate approximately $360 million in net sales for 2025. To put that in perspective, that's less than 10% of the company's estimated annual net sales of $4.3 billion for 2025. Because the external environment has shifted, Perrigo Company plc is currently conducting a strategic review of this business, which includes reassessing a previously announced $240 million investment.

Finally, you have the customers seeking specialized, higher-margin self-care brands. These consumers are the target for the 'High-Grow' brands that Perrigo Company plc prioritizes investment in. In the CSCI segment, which focuses outside the U.S. and Canada, revenue generation is primarily through these national brands, such as Compeed®, Solpadeine®, and ellaOne®. These are the areas management is strengthening to drive better returns, contrasting with the cash-generating store brand business.

Finance: draft 13-week cash view by Friday.

Perrigo Company plc (PRGO) - Canvas Business Model: Cost Structure

You're looking at the hard numbers driving Perrigo Company plc's operational expenses as of late 2025. This structure is heavily influenced by manufacturing scale, ongoing efficiency programs, and necessary innovation spending.

The cost of goods sold (COGS) remains a major component, reflecting the scale of manufacturing and supply chain complexity in the consumer self-care space. For the fiscal quarter ending June 2025, the reported Cost of Sales was $666.2 million. This is reflected in the reported gross margin for the second quarter of 2025, which stood at 26.2%, with an adjusted gross margin of 28.2%. To be fair, the company is also managing potential external cost shocks; Perrigo estimated a gross increase to global COGS in 2025, beginning in the fourth quarter, of approximately $10 million to $20 million, with a full-year impact around $50 million to $60 million, potentially due to pharmaceutical tariffs.

A significant part of the current cost management focus is Project Energize, an efficiency program launched in the first quarter of 2024. This initiative is designed to reset the SG&A operating expense base and drive organizational agility. As of the second quarter of 2025, Project Energize had achieved gross annual savings of approximately $159 million since its inception, with $27 million reinvested. The program is expected to deliver total annualized pre-tax savings in the range of $140 million to $170 million by the end of 2026, with $40 million to $60 million of those savings expected to be reinvested. The associated restructuring and related charges are estimated to total between $140 million to $160 million through 2026, which includes $20 million to $40 million earmarked for capability enhancement investments.

Investment in Research and development (R&D) is necessary to fuel consumer-led innovation and maintain brand relevance. You can see the impact on operating expenses; for instance, in the second quarter of 2025, lower R&D investments provided a partial offset to the decrease in Adjusted Operating Income, alongside lower advertising and promotional (A&P) spend and Project Energize benefits. This shows a balancing act between cost discipline and necessary spending on future growth drivers like Opill® and other brand activations.

Finally, the balance sheet reflects substantial financial obligations that impact financing costs. Perrigo Company plc reported total debt of $3.65 billion as of June 28, 2025. This debt level results in an interest coverage ratio of 2.5x, with total debt at $3.65B against total assets of $10.08B. Lower interest expense from reduced debt was a positive driver for Adjusted EPS in the second quarter of 2025.

Here's a quick look at some key financial metrics impacting the cost base as of the end of Q2 2025:

Financial Metric	Amount/Value (as of June 28, 2025)
Total Debt	$3.65 billion
Cash and Cash Equivalents	$454 million
Reported Gross Margin (Q2 2025)	26.2%
Adjusted Gross Margin (Q2 2025)	28.2%
Project Energize Gross Annual Savings Achieved (to Q2 2025)	$159 million
Project Energize Reinvestment (to Q2 2025)	$27 million
Estimated Total Restructuring Charges for Project Energize	$140 million to $160 million

The ongoing commitment to Project Energize savings, alongside the management of COGS pressures and strategic R&D allocation, defines the near-term cost structure for Perrigo Company plc. Finance: draft 13-week cash view by Friday.

Perrigo Company plc (PRGO) - Canvas Business Model: Revenue Streams

Perrigo Company plc generates its revenue primarily through the sale of its Consumer Self-Care products across two main operating segments. The financial performance for the third quarter of fiscal year 2025 provides a clear snapshot of the current revenue contribution by geography.

For the third quarter of 2025, total reported net sales for Perrigo Company plc were $1,043.3 million. Year-to-date net sales through the first nine months of 2025 reached $3,143.5 million.

The segment breakdown for the third quarter of 2025 net sales is as follows:

Revenue Stream Component	Q3 2025 Net Sales Amount
Net sales from Consumer Self-Care Americas (CSCA) segment	$646 million
Net sales from Consumer Self-Care International (CSCI) segment	$398 million

The composition of the revenue mix leans heavily on private label offerings, though specific 2025 segment sales figures for private label versus branded are not explicitly broken out in the latest reports, a June 2025 presentation indicated the following revenue split:

Revenue Type	Approximate Revenue Mix (as of June 2025)
Sales of store brand/private label OTC products	60%
Sales of national/High-Grow brands	40%

Within the national/High-Grow brands category, specific products show significant momentum. For instance, the Mederma® brand (referred to as the Moderna Brand in one source) saw its net sales increase by over 35%. Conversely, the impact of the Opill® launch stocking benefit in the prior year resulted in a -0.5% drag on year-to-date 2025 organic net sales.

Perrigo Company plc has updated its expectations for the full fiscal year 2025, factoring in industry dynamics and consumption trends. The projection for the full-year 2025 net sales growth is set between -2.5% to -3.0%.

The Infant Formula business, which is currently undergoing a strategic review, was expected to generate approximately $360 million in net sales for the full year 2025, representing less than 10% of the Company's total annual net sales.

The company is focused on driving growth through its key brands, with management aiming for $100-$200 million in incremental revenue from high-growth brands by 2027.